Clinical Trial Update: The Role of FGF23 and Asymmetric Dimethylarginine (ADMA) in Chronic Kidney Disease

View source ↗

Summary

Clinical trial exploring the roles of FGF23 and dimethylarginine in chronic kidney disease, sponsored by Ankara Education and Research Hospital; current status …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease

Snippet

Sponsor: Ankara Education and Research Hospital | Conditions: Metabolic Diseases, Chronic Kidney Disease | Status: UNKNOWN